Trending Stock News

$-0.57 EPS Expected for Ovid Therapeutics Inc. (OVID)

Analysts expect Ovid Therapeutics Inc. (NASDAQ:OVID) to report $-0.57 EPS on November, 8.They anticipate $0.19 EPS change or 50.00 % from last quarter’s $-0.38 EPS. After having $-0.53 EPS previously, Ovid Therapeutics Inc.’s analysts see 7.55 % EPS growth. The stock decreased 0.67% or $0.04 during the last trading session, reaching $5.95. About 38,850 shares traded. Ovid Therapeutics Inc. (NASDAQ:OVID) has declined 28.62% since October 24, 2017 and is downtrending. It has underperformed by 44.24% the S&P500.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company has market cap of $146.56 million. The firm is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome. It currently has negative earnings. It is also developing OV935, a drug candidate that is in Phase I trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the hospital setting.

More important recent Ovid Therapeutics Inc. (NASDAQ:OVID) news were published by: which released: “Ovid Therapeutics Receives “Company Making a Difference Award” from CDKL5 Deficiency Disorder Community” on October 22, 2018, also published article titled: “Key events next week – healthcare”, published: “Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 am EDT” on October 22, 2018. More interesting news about Ovid Therapeutics Inc. (NASDAQ:OVID) was released by: and their article: “Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with …” with publication date: September 24, 2018.

Ovid Therapeutics Inc. (NASDAQ:OVID) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *